Patents Assigned to Genentech
  • Therapeutic and diagnostic methods for cancer
    Patent number: 11535671
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.
    Type: Grant
    Filed: October 17, 2019
    Date of Patent: December 27, 2022
    Assignee: Genentech, Inc.
    Inventors: Priti Hegde, Marcin Kowanetz, Gregg Fine, Sanjeev Mariathasan, Richard Bourgon
  • INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE
    Publication number: 20220403034
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including Crohn's disease are provided. Also provided are methods of administering and dosing integrin beta7 antagonists, such as anti-integrin beta7 antibodies. In addition, methods of administrating and dosing such integrin beta7 antagonists to induce remission or to induce and maintain remission of Crohn's disease are provided.
    Type: Application
    Filed: February 3, 2022
    Publication date: December 22, 2022
    Applicant: GENENTECH, INC.
    Inventors: Azra Hassanali, Romeo Maciuca, Meina Tao Tang, Swati Tole, Xiaohui Wei
  • METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20220403033
    Abstract: Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of administering integrin beta7 antagonists, such as anti-beta7 antibodies. In addition, particular dosing regimens, including dosing regimens comprising subcutaneous administration and administration using self-inject devices are provided.
    Type: Application
    Filed: February 3, 2022
    Publication date: December 22, 2022
    Applicant: GENENTECH, INC.
    Inventors: Banmeet Anand, Eric Stefanich, Meina Tang, Jennifer Visich, Marna Williams, Sharon O'Byrne
  • Anti-CD3 antibodies and methods of use
    Patent number: 11530275
    Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: December 20, 2022
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Teemu T. Junttila, Robert F. Kelley, Mary A. Mathieu
  • RAPID DEPRESSURIZATION CONTROLLED ICE NUCLEATION IN PHARMACEUTICAL FREEZE-DRYING
    Publication number: 20220397346
    Abstract: A lyophilization method for lyophilizing products inside one or more vials within a lyophilization chamber is disclosed which includes humidifying a charge gas to a predetermined relative humidity, cooling shelves in the lyophilization chamber to a predetermined temperature, pressurizing the chamber with the humidified charge gas to a pressurization threshold to thereby achieving a target relative humidity level within the lyophilization chamber, and suddenly releasing pressure within the lyophilization chamber until a depressurization threshold is reached in a short time interval up to about 4 seconds, during the depressurization, product inside one or more vials nucleate.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 15, 2022
    Applicants: Purdue Research Foundation, Genentech, Inc.
    Inventors: Andrew Strongrich, Alina Alexeenko, Fredric John Lim, Lokesh Kumar
  • Apparatus and methods for sealing a medicament within a medical delivery device
    Patent number: 11523969
    Abstract: Apparatus and methods for lyophilizing and sealing a medicament within a medical delivery device having an opening. The apparatus may include a stopper for sealing the opening. The stopper may have one or more elongated members extending from a base, in a direction that is parallel to a central axis of the base. One or more of the members may be set radially away from the axis and define a coaxial central well. The member or members may define a void. The elongated member or members may engage a device inner wall and support the base away from the opening. The void may provide gas exchange between a device interior and a device exterior. The gas may be a lyophilization byproduct that escapes from the device interior between the inner wall, the base and the member or members. The stopper may be advanced into the device to seal the opening.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: December 13, 2022
    Assignee: Genentech, Inc.
    Inventor: Lionel Vedrine
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20220389020
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: January 14, 2022
    Publication date: December 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • Agonists of TREM2
    Publication number: 20220389097
    Abstract: This application discloses, inter alia, certain antibodies that specifically bind to human TREM2 (triggering receptor expressed on myeloid cells 2). In some embodiments, the antibodies act as TREM2 agonists. In some embodiments, antibodies herein specifically bind to the stalk region of intact, human TREM2, without binding to soluble TREM2, which is the product of TREM2 cleavage between residues H157 and S158. In some embodiments, the antibodies act as TREM2 agonists, specifically bind to the stalk region of TREM2 with dissociation constants ranging from 10 nM to as low as 100-500 pM, 10-50pM, or 1-10 pM, specifically bind to a TREM2 epitope spanning the H157-S158 cleavage site, and do not bind to soluble TREM2.
    Type: Application
    Filed: May 12, 2022
    Publication date: December 8, 2022
    Applicant: Genentech Inc.
    Inventors: Ainhoa Echeverria Larraza, David Verne Hansen, Isidro Hotzel, Yi-Chun Hsiao, Zhonghua Lin, Dhaya Seshasayee, Benny Chih
  • Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
    Patent number: 11519912
    Abstract: Monoclonal and polyclonal antibodies that bind hamster phospholipase B-like 2 are provided. Also provided are methods for detecting and quantifying hamster phospholipase B-like 2, for example, in recombinant polypeptide preparations, as well as kits for carrying out such methods. Methods of screening or selecting host cell lines or recombinant polypeptide-expressing cell lines that express low levels of hamster phospholipase B-like 2 are also provided.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: December 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Feny Gunawan, Yi-Chun Hsiao, Denise C. Krawitz, Margaret S. Lin, Martin Vanderlaan, Rajesh Vij, Inn H. Yuk, Judith Zhu-Shimoni
  • CLASS-DISPARATE LOSS FUNCTION TO ADDRESS MISSING ANNOTATIONS IN TRAINING DATA
    Publication number: 20220383621
    Abstract: A data set can be provided that includes an input data element and one or more label data portion definitions that each identify a feature of interest within the input data element. A machine-learning model can generate model-identified portions definitions that identify predicted feature of interests within the input data element. At least one false negative (where a feature of interest is identified without a corresponding predicted feature of interest) and at least one false positive (where a predicted feature of interest is identified without a corresponding feature of interest) can be a identified. A class-disparate loss function can be provided that is configured to penalize false negatives more than at least some false positives. A loss can be calculated using the class-disparate loss function. A set of parameter values of the machine-learning model can be determined based on the loss.
    Type: Application
    Filed: August 10, 2022
    Publication date: December 1, 2022
    Applicant: Genentech, Inc.
    Inventor: Jasmine PATIL
  • METHODS OF INDUCING NEOEPITOPE-SPECIFIC T CELLS WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE
    Publication number: 20220378910
    Abstract: The present disclosure provides methods for inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual using an RNA vaccine or using an RNA vaccine in combination with a PD-1 axis binding antagonist. Also provided herein are PD-1 axis binding antagonists and RNA vaccines that include one or more polynucleotides encoding one or more neoepitopes resulting from cancer-specific somatic mutations present in a tumor specimen obtained from the individual for use in methods of inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 1, 2022
    Applicants: Genentech, Inc., BioNTech SE, Hoffmann-La Roche Inc.
    Inventors: Lars MUELLER, Rachel Lubong SABADO, Mahesh YADAV, Jingbin ZHANG, Ugur SAHIN
  • Anti-HtrA1 antibodies and methods of use thereof
    Patent number: 11512143
    Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: November 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Daniel K. Kirchhofer, Joyce Lai, Chingwei V. Lee, Wei-Ching Liang, Michael T. Lipari, Kelly M. Loyet, Tao Sai, Menno Van Lookeren Campagne, Yan Wu, Germaine Fuh
  • Methods for assaying T-cell dependent bispecific antibodies
    Patent number: 11513127
    Abstract: The present invention provides a cell-based assay for measuring T cell activation mediated by a T cell-dependent bispecific antibody (TDB). In some aspects, the assay is useful for detecting a TDB in a composition, quantitating the amount of TDB in a composition, determining the potency and/or specificity of a TDB, or determining if a population of cells expresses a target antigen. Compositions and kits are also contemplated.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: November 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Ho Young Lee, Guoying Jiang, Pin Yee Wong, Kendall Carey
  • MEASURING CHANGE IN TUMOR VOLUMES IN MEDICAL IMAGES
    Publication number: 20220375116
    Abstract: Techniques disclosed herein facilitate tracking the degree to which a size of a biological structure changes over time. In some instances, an initial biological image (collected at a first time) can be segmented to characterized a boundary and size. A subsequent biological image can be processed to identify a deformation and/or transformation variable (e.g., one or more Jacobian matrices and/or one or more Jacobian determinants). The deformation and/or transformation variable(s) and initial segmentation can be used to predict a size of the biological structure at a subsequent time. The predicted size may inform a treatment recommendation.
    Type: Application
    Filed: June 27, 2022
    Publication date: November 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Jasmine PATIL, Alexander James Stephen CHAMPION DE CRESPIGNY, Richard Alan Duray CARANO
  • METHODS OF CONJUGATING AN AGENT TO A THIOL MOIETY IN A PROTEIN THAT CONTAINS AT LEAST ONE TRISULFIDE BOND
    Publication number: 20220372141
    Abstract: The invention provides improved methods of conjugating an agent to a thiol moiety in a protein that contains at least one disulfide bond and at least one trisulfide bond. Exemplary embodiments include the production of antibody drug conjugates substantially free of impurities created in the presence of reactive sulfide moieties in the production processes.
    Type: Application
    Filed: May 24, 2022
    Publication date: November 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Jayme FRANKLIN, Xin Xin LIN, Jeffrey GORRELL, Timothy TULLY, Matthew HUTCHINSON, Charity Tucker BECHTEL
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20220370441
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: November 24, 2022
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • SPIROCYCLIC 2,3-DIHYDRO-7-AZAINDOLE COMPOUNDS AND USES THEREOF
    Publication number: 20220370420
    Abstract: Spirocyclic 2,3-dihydro-7-azaindole compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the spirocyclic 2,3-dihydro-7-azaindole compounds.
    Type: Application
    Filed: March 17, 2021
    Publication date: November 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Craig Stivala, BinQing Wei, Bryan K. Chan, Timothy Heffron, Michael Lainchbury, Andrew Madin, Terry Aaron Panchal, Eileen Mary Seward, Toby Blench, Matthew W. Cartwright, Elsa Amandine Dechaux, Richard Elliott, Emanuela Gancia
  • Deuterated compounds
    Patent number: 11504440
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: November 22, 2022
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20220362379
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS
    Publication number: 20220363772
    Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Application
    Filed: February 22, 2022
    Publication date: November 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Craig SMITH, Peter S. CHIN